Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 11413278
Compounds and methods for promoting stress resistance
granted -
US 11414455
Toll-like receptor 2 ligands and methods of making and using thereof
granted -
US 11414423
Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders
granted -
US 11413420
Nitric oxide delivery devices
granted -
US 11414644
Methods of recellularizing a tissue or organ for improved transplantability
granted -
US 11413240
Methylene blue solution for the treatment of oral lesions
granted -
US 11413336
Coccidioides antigens and methods of their use
granted -
US 11413301
Composition comprising sea cucumber extract as effective ingredient for preventing and treating Bruch's membrane dysfunction-related disease
granted -
US 11413329
Cancer cell trap
granted -
US 11413296
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 11406656
Methods and compositions for administration of iron
granted -
US 11407998
Twist signaling inhibitor compositions and methods of using the same
granted -
US 11407990
Fusion proteins and methods for site-directed genome editing
granted -
US 11406597
Fusogenic liposome-coated porous silicon nanoparticles
granted -
US 11406722
Nanodroplets with improved properties
granted -
US 11407649
Cerium (III) carbonate formulations
granted -
US 11407752
Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3β²-indoline]-2β²,5(3H)-dione analogues
granted -
US 11407820
Modulating the alternative complement pathway
granted -
US 11406643
Targeting kinases for the treatment of cancer metastasis
granted -
US 11406697
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
granted -
US 11406616
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
granted -
US 11406720
Fibroblast growth factor receptor 2-specific peptide reagents and methods
granted -
US 11406721
Compositions and methods for imaging cell populations
granted -
US 11401332
Proteolytically cleavable chimeric polypeptides and methods of use thereof
granted -
US 11400118
Methods for production of platelets from pluripotent stem cells and compositions thereof
granted -
US 11400116
Systems and methods for targeting cancer cells
granted -
US 11400096
Small molecules for the treatment of autoimmune disorders
granted -
US 11401510
Generation of airway basal stem cells from human pluripotent stem cells
granted -
US 11401506
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
granted -
US 11400284
Method of transcutaneous electrical spinal cord stimulation for facilitation of locomotion
granted -
US 11401532
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11400143
Compositions and methods for treatment of homocystinuria
granted -
US 11400098
Method of treating microbial infections
granted -
US 11400104
Skeletal removal of bisphosphonates
granted -
US 11400108
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
granted -
US 11396571
Polymers including galactose based blocks and uses thereof
granted -
US 11397188
Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
granted -
US 11396647
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
granted -
US 11395838
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
granted -
US 11395850
RSV vaccines and methods of production and use thereof
granted -
US 11389663
Laser assisted wound healing protocol and system
granted -
US 11389386
Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens
granted -
US 11390848
Materials and methods for modifying the activity of T cells
granted -
US 11390667
Compositions and methods for the treatment of neuromyelitis optica
granted -
US 11389396
Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections
granted -
US 11389482
Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 11389459
Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
granted -
US 11390646
Structure-based peptide inhibitors of Ξ±-synuclein aggregation
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory